United Therapeutics wins on appeal against Sandoz's US antitrust claims over Remodulin
MLex Summary: United Therapeutics has sufficiently shown procompetitive justifications for its acquisition of all commercially available cartridges required for administering treprostinil under the skin through a wearable pump, according to a...To view the full article, register now.
Already a subscriber? Click here to view full article